Full analysis and usage recommendations of cansezizumab usage and dosage

Concizumab (trade name Alhemo), as an innovative biological agent, is widely used in patients aged 12 years and above with hemophilia A (congenital factor) and FVIII inhibitors. span>VIII deficiency) or in patients treated with FIX inhibitors for hemophiliaB (congenital factor IX deficiency), for routine use to prevent the occurrence or reduce the frequency of bleeding events.

Cancelizumab is administered by subcutaneous injection in the abdomen or thigh, and the injection site should be rotated daily to avoid local discomfort. The recommended dosage regimen is as follows:

Initial dose:

Day : Give loading dose 1mg/kg (mg/kg).

Maintenance dose:

Starting on day , the dose is 0.2 mg/kg once daily until the individualized maintenance dose is determined.

Dose adjustment:

Concizumab () -mtci plasma concentrations should be measured by Concizumab Enzyme-Linked Immunosorbent Assay (ELISA) 4 weeks after initiation of treatment for the purpose of dosing optimization before administration of the next scheduled dose. Although there are currently no FDA-authorized tests to measure concentrations of concizumab-mtci in plasma, this step is critical for individualizing treatment.

Adjust the maintenance dose based onconcizumab-mtciplasma concentration:

Less than200nanogram/Milliliter (ng/mL): Adjust to a once-daily dose of 0.25 mg/kg.

200to4000 ng/mL: Continue once daily dose of 0.2 mg/kg.

Greater4000 ng/mL: Adjust to once daily dose0.15 mg/kg.

It should be noted that the dose of cancelizumab needs to be adjusted according to individual conditions. Patients should strictly follow the doctor's instructions and are not allowed to increase or decrease the dose on their own. During treatment, concizumab-mtci plasma concentration and the occurrence of bleeding events should be regularly monitored so that the treatment plan can be adjusted in a timely manner. In addition, the injection site should be rotated every day to avoid repeated injections at the same site to reduce local discomfort and the formation of subcutaneous induration. At the same time, concezizumab needs to be stored properly and away from direct sunlight and high temperature environment to avoid affecting the efficacy of the drug.

As an effective drug for the treatment of hemophilia, the usage and dosage of cancelizumab must be strictly followed by the doctor's instructions, and the patient's condition must be closely monitored during treatment to ensure the safety and effectiveness of the treatment.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761315s000lbl.pdf